CONSISTENCY OF LDL-C REDUCTION WITH EVOLOCUMAB: AN ANALYSIS FROM FOURIER
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)32268-x
Abstract: Questions have been raised about interpatient variability in response to PCSK9 inhibitors. FOURIER was a randomized, pbo-controlled trial of the PCSK9i evolocumab, a fully human mAb, in pts w/ ASCVD on a statin. We examined… read more here.
Keywords: consistency ldl; reduction evolocumab; ldl reduction; evolocumab ... See more keywords